Less is More? First Impressions From COSMIC-313

References

• Choueiri TK, Powles TB, Albiges L, Burotto C, Szczylik B, Zurawski E, et al. LBA8 - phase 3 study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Ann Oncol. 2022;33(suppl_7):S808–S869.
   Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–148. doi:10.1016/S1470-2045(12)70559-4.
   PubMed Web of Science ®Google Scholar
• Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade-a winning combination in cancer treatment? Expert Opin Ther Targets. 2021;25(2):141–151. doi:10.1080/14728222.2021.1869212.
   PubMed Web of Science ®Google Scholar
• Meza L, Malhotra J, Favorito C, Pal SK. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncol. 2022;18(1):21–33. doi:10.2217/fon-2021-0570.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. doi:10.1056/NEJMoa2026982.
   PubMed Web of Science ®Google Scholar
• Msaouel P. The big data paradox in clinical practice. Cancer Invest. 2022;40(7):567–576. doi:10.1080/07357907.2022.2084621.
   PubMed Web of Science ®Google Scholar
• van Zwet E, Schwab S, Greenland S. Addressing exaggeration of effects from single RCTs. Significance. 2021;18(6):16–21. doi:10.1111/1740-9713.01587.
   Google Scholar
• Zwet EW, Cator EA. The significance filter, the winner’s curse and the need to shrink. Stat Neerl. 2021;75(4):437–452. doi:10.1111/stan.12241.
   Web of Science ®Google Scholar
• van Zwet E, Schwab S, Senn S. The statistical properties of RCTs and a proposal for shrinkage. Stat Med. 2021;40(27):6107–6117. doi:10.1002/sim.9173.
   PubMed Web of Science ®Google Scholar
• Rafi Z, Greenland S. Semantic and cognitive tools to aid statistical science: replace confidence and significance by compatibility and surprise. BMC Med Res Methodol. 2020;20(1):244. doi:10.1186/s12874-020-01105-9.
   PubMed Web of Science ®Google Scholar
• Kotecha RR, Hsu DJ, Lee C-H, Patil S, Voss MH. In silico modeling of combination systemic therapy for advanced renal cell carcinoma. J Immunother Cancer. 2021;9(12):e004059. doi:10.1136/jitc-2021-004059.
   PubMed Web of Science ®Google Scholar
• Plana D, Palmer AC, Sorger PK. Independent drug action in combination therapy: implications for precision oncology. Cancer Discov. 2022;12(3):606–624. doi:10.1158/2159-8290.CD-21-0212.
   PubMed Web of Science ®Google Scholar
• Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell. 2017;171(7):1678–1691 e13. doi:10.1016/j.cell.2017.11.009.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi:10.1056/NEJMoa1816047.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714.
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi:10.1056/NEJMoa2035716.
   PubMed Web of Science ®Google Scholar
• Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. doi:10.1136/esmoopen-2020-001079.
   PubMed Web of Science ®Google Scholar
• Msaouel P, Grivas P, Zhang T. Adjuvant systemic therapies for patients with renal cell carcinoma: choosing treatment based on patient-level characteristics. Eur Urol Oncol. 2022;5(3):265–267. doi:10.1016/j.euo.2021.09.003.
   PubMedGoogle Scholar
• Msaouel P. Impervious to randomness: confounding and selection biases in randomized clinical trials. Cancer Invest. 2021;39(10):783–788. doi:10.1080/07357907.2021.1974030.
   PubMed Web of Science ®Google Scholar
• Weir CJ, Taylor RS. Informed decision-making: statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments. Pharm Stat. 2022;21(4):740–756. doi:10.1002/pst.2219.
   PubMed Web of Science ®Google Scholar
• Valentí V, Jiménez-Fonseca P, Msaouel P, Salazar R, Carmona-Bayonas A. Fooled by randomness. The misleading effect of treatment crossover in randomized trials of therapies with marginal treatment benefit. Cancer Invest. 2022;40(2):184–188. doi:10.1080/07357907.2021.2020281.
   PubMed Web of Science ®Google Scholar
• Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. J Am Stat Assoc. 2012;107(498):493–508. doi:10.1080/01621459.2011.641416.
   PubMed Web of Science ®Google Scholar
• Xu Y, Müller P, Wahed AS, Thall PF. Bayesian nonparametric estimation for dynamic treatment regimes with sequential transition times. J Am Stat Assoc. 2016;111(515):921–935. doi:10.1080/01621459.2015.1086353.
   PubMed Web of Science ®Google Scholar
• Msaouel P, Lee J, Thall PF. Making patient-specific treatment decisions using prognostic variables and utilities of clinical outcomes. Cancers (Basel). 2021;13(11):2741. doi:10.3390/cancers13112741.
   PubMed Web of Science ®Google Scholar
• Senn S. Testing for baseline balance in clinical trials. Stat Med. 1994;13(17):1715–1726. doi:10.1002/sim.4780131703.
   PubMed Web of Science ®Google Scholar
• Morris TP, Walker AS, Williamson EJ, White IR. Planning a method for covariate adjustment in individually randomised trials: a practical guide. Trials. 2022;23(1):328. doi:10.1186/s13063-022-06097-z.
   PubMed Web of Science ®Google Scholar
• Mansournia MA, Higgins JPT, Sterne JAC, Hernán MA. Biases in randomized trials: a conversation between trialists and epidemiologists. Epidemiology. 2017;28(1):54–59. doi:10.1097/EDE.0000000000000564.
   PubMed Web of Science ®Google Scholar
• Hahn AW, Dizman N, Msaouel P. Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive. Ther Adv Med Oncol. 2022;14:17588359221103199. doi:10.1177/17588359221103199.
   Web of Science ®Google Scholar
• Cuzick J. Prognosis vs treatment interaction. JNCI Cancer Spectr. 2018;2(1):pky006. doi:10.1093/jncics/pky006.
   PubMed Web of Science ®Google Scholar
• Msaouel P, Lee J, Karam JA, Thall PF. A causal framework for making individualized treatment decisions in oncology. Cancers (Basel). 2022;14(16):3923. doi:10.3390/cancers14163923.
   PubMed Web of Science ®Google Scholar
• Lee J, Thall PF, Msaouel P. Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity. Biometrics. 2022. doi:10.1111/biom.13738.
   Web of Science ®Google Scholar
• Lee J, Thall PF, Msaouel P. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups. Stat Med. 2021;40(24):5199–5217. doi:10.1002/sim.9120.
   PubMed Web of Science ®Google Scholar
• Lee J, Thall PF, Lim B, et al. Utility-based Bayesian personalized treatment selection for advanced breast cancer. J R Stat Soc Ser C. In press. doi:10.1111/rssc.12582.
   Web of Science ®Google Scholar
• Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, et al. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer. 2021;149(2):387–393. doi:10.1002/ijc.33560.
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Buti S, Ghidini A, Tiseo M, Petrelli F. A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick? Anticancer Drugs. 2020;31(3):211–215. doi:10.1097/CAD.0000000000000883.
   PubMed Web of Science ®Google Scholar
• Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol. 2021;7(12):1815–1823. doi:10.1001/jamaoncol.2021.4544.
   PubMed Web of Science ®Google Scholar
• Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini B, et al. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA A Cancer J Clinicians. 2022;72(5):454–489. doi:10.3322/caac.21729.
   PubMed Web of Science ®Google Scholar
• Shapiro DD, Msaouel P. Causal diagram techniques for urologic oncology research. Clin Genitourin Cancer. 2021;19(3):271 e1–271 e7. doi:10.1016/j.clgc.2020.08.003.
   PubMed Web of Science ®Google Scholar
• Liu K, Meng X-L. There is individualized treatment. Why not individualized inference? Annu Rev Stat Appl. 2016;3(1):79–111. doi:10.1146/annurev-statistics-010814-020310.
   Google Scholar
• Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic therapies for the management of non-clear cell renal cell carcinoma: what works, what doesn’t, and what the future holds. Clin Genitourin Cancer. 2021;19(2):103–116. doi:10.1016/j.clgc.2020.11.005.
   PubMed Web of Science ®Google Scholar
• Thouvenin J, Alhalabi O, Carlo M, et al. Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas. Oncologist. 2022; doi:10.1093/oncolo/oyac158.
   PubMed Web of Science ®Google Scholar
• Senn S. Seven myths of randomisation in clinical trials. Stat Med. 2013;32(9):1439–1450. doi:10.1002/sim.5713.
   PubMed Web of Science ®Google Scholar
• Kaufman S, Kaufman JS, Maclehose RF. Analytic bounds on causal risk differences in directed acyclic graphs involving three observed binary variables. J Stat Plan Inference. 2009;139(10):3473–3487. doi:10.1016/j.jspi.2009.03.024.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
   Google Scholar
• Cornelius V, Cro S, Phillips R. Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials. Trials. 2020;21(1):1028. doi:10.1186/s13063-020-04903-0.
   PubMed Web of Science ®Google Scholar
• Adashek JJ, Genovese G, Tannir NM, Msaouel P. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: a review of the evidence using second-generation p-values. Cancer Treat Res Commun. 2020;23:100166. doi:10.1016/j.ctarc.2020.100166.
   PubMedGoogle Scholar